Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pilot and Numeric Relaying

Pilot and Numeric Relaying

Pilot relaying is a type of differential protection used in power systems. It compares electrical quantities at the terminals of equipment via a communication channel instead of direct relay interconnection. This method is essential for transmission lines where the terminals are far apart, typically up to 80 km for lines with 69 to 115 kV ratings. Four types of communication channels are used for pilot relaying:

Self-Efficacy

Self-Efficacy

Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Aneurysm II: Clinical Manifestations and Diagnostic Studies

Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Serial high-resolution ultrasonography demonstrates dynamic inflammatory changes during multidrug therapy in leprosy neuropathy: a longitudinal case report.

BMC neurology·2026

Same author

Atypical pemphigus foliaceus with pustular lesions: a case series.

Journal of medical case reports·2026

Same author

Rapidly Progressive Perianal Giant Condyloma in an Immunocompetent Adolescent: An Unusual Abuse-Associated Case.

Clinical, cosmetic and investigational dermatology·2026

Same author

The Uncommon Coexistence of Mid-Borderline Leprosy and Generalized Pustular Psoriasis.

Clinical, cosmetic and investigational dermatology·2026

Same author

Atopic Dermatitis in Urban Indonesian Children: A Case-Control Study of the Prevalence of Filaggrin Loss-of-Function Variants and Sociodemographic Factors at a Tertiary Referral Hospital.

Dermatology (Basel, Switzerland)·2026

Same author

Leprosy in Pregnancy: A Systematic Review of Maternal Characteristics, Complications, and Neonatal Outcomes.

International journal of women's health·2026

Search research articles

Related Experiment Video

Updated: Feb 9, 2026

Author Spotlight: Treating Frozen Shoulder with Small Needle Knife Therapy

Author Spotlight: Treating Frozen Shoulder with Small Needle Knife Therapy

Published on: November 17, 2023

Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy.

Hendra Gunawan¹, Muljaningsih Sasmojo¹, Helena Eka Putri¹

¹Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia.

International Journal of Mycobacteriology

|June 15, 2018

Summary

Clarithromycin effectively treats multibacillary leprosy, showing comparable results to rifampicin in a 3-month clinical study. This offers a new alternative for patients with rifampicin resistance or allergies.

Keywords:

Clarithromycin leprosy rifampicin

More Related Videos

Video Movement Analysis Using Smartphones ViMAS: A Pilot Study

Video Movement Analysis Using Smartphones ViMAS: A Pilot Study

Published on: March 14, 2017

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

Related Experiment Videos

Last Updated: Feb 9, 2026

Author Spotlight: Treating Frozen Shoulder with Small Needle Knife Therapy

Author Spotlight: Treating Frozen Shoulder with Small Needle Knife Therapy

Published on: November 17, 2023

Video Movement Analysis Using Smartphones ViMAS: A Pilot Study

Video Movement Analysis Using Smartphones ViMAS: A Pilot Study

Published on: March 14, 2017

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

Area of Science:

Infectious Diseases
Dermatology
Pharmacology

Background:

Rifampicin is a key component of multidrug therapy (MDT) for leprosy.
Clarithromycin presents an alternative therapeutic option to rifampicin.

Purpose of the Study:

To compare the efficacy of clarithromycin (2,000 mg) versus rifampicin (600 mg) in multibacillary (MB) leprosy patients.
Both drugs were administered in combination with dapsone and clofazimine for 3 months.

Main Methods:

A pilot clinical study involving two groups of seven MB leprosy patients each.
One group received the standard MDT-MB regimen (rifampicin-dapsone-clofazimine).
The other group received the clarithromycin-dapsone-clofazimine (CDC) regimen.

Main Results:

The clarithromycin-dapsone-clofazimine group showed a significant reduction in the morphological index (MI) (P = 0.004).
The MDT-MB group had an insignificant MI reduction (P = 0.248).
No significant difference in MI reduction was observed between the groups (P = 0.130). Mild nausea occurred in the CDC group, and red urine in the MDT-MB group.

Conclusions:

Clarithromycin (2,000 mg) is as effective as rifampicin (600 mg) in combination regimens for MB leprosy.
Clarithromycin can serve as an alternative treatment for leprosy patients with rifampicin resistance or allergy.